The Medical Letter on Drugs and Therapeutics
Pneumococcal Vaccine for Adults
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The US Advisory Committee on Immunization Practices (ACIP) has recommended that adults with immunocompromising conditions receive the 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13), even if they have already received the older 23-valent unconjugated vaccine (PPSV23; Pneumovax 23).1 Prevnar 13, initially approved by the FDA for use in infants and young children,2 has been licensed since December 2011 for adults ≥50 years old.

PNEUMOCOCCAL DISEASE — The pneumococcal serotypes in PCV13 cause about two-thirds of the cases of invasive pneumococcal disease (IPD) in children <5 years old and about half of those in immunocompromised adults. The incidence of pneumococcal pneumonia, bacteremia, and meningitis is about 10 times higher in patients ≥65 years old than in young adults. In immunocompromised adults, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Pneumococcal Vaccine for Adults
Article code: 1402b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian